

CEPHEUS - Assessment of lipid-lowering treatment in France

Head :Ferrières Jean, Département d'épidémiologie INSERM UMR1027

Last update : 09/05/2017 | Version : 3 | ID : 6396

General

Identification

Detailed name Assessment of lipid-lowering treatment in France

Sign or acronym CEPHEUS

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL méthodologie de référence MR-001; Avis favorable n° 2-06-14/Avis n°2 du CCPPRB Toulouse II du 5 mai 2006; Avis favorable AFSSAPS n°060544 du 25 août 2006

General Aspects

Medical area Cardiology
Hematology

Keywords Guidelines, LDL cholesterol, Lipid-lowering drugs, Statins, France

Scientific investigator(s) (Contact)

Name of the director Ferrières

Surname Jean

Address Faculté de médecine 37 allée Jules Guesde 31073
Toulouse Cedex

Phone +33 (0)5 61 14 59 49

Email jean.ferrieres@univ-toulouse.fr

Unit Département d'épidémiologie INSERM UMR1027

Organization CHU de

Collaborations

Funding

Funding status Private

Details	Astra Zeneca (laboratoire pharmaceutique)
Governance of the database	
Sponsor(s) or organisation(s) responsible	CHU de toulouse
Organisation status	Public
Sponsor(s) or organisation(s) responsible	Promoteur : Astra Zeneca SAS 92844 Rueil Malmaison
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	All included patients visiting a general practitioner for any reason and corresponding to the criteria are invited to participate.
Database objective	
Main objective	Determine the proportion of patients on lipid-lowering drugs who reach the LDL-C goals recommended in guidelines.
Inclusion criteria	man or woman - adult - treated with lipid-lowering drugs for at least three months, with no dose adjustment for a minimum of six weeks
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years)

Population covered	Sick population
Gender	Male Woman
Geography area	International
Detail of the geography area	8 european countries: Belgium, France, Greece, Ireland, Netherlands, Finland, Turkey and Luxembourg
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	05/2006
Date of last collection (YYYY or MM/YYYY)	12/2006
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1966 french subjects
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data Biological data
Clinical data (detail)	Medical registration
Declarative data (detail)	Paper self-questionnaire
Biological data (detail)	fasting blood sample
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health care consumption and services
Care consumption (detail)	Hospitalization Medical/paramedical consultation Medicines consumption

Procedures

Participant monitoring No

Links to administrative sources No

Promotion and access

Promotion

Link to the document <http://www.sciencedirect.com/science/article/pii/S1875213608001150>

Access

Terms of data access (charter for data provision, format of data, availability delay) Contact scientific investigator.

Access to aggregated data Access on specific project only

Access to individual data Access on specific project only